# ZAYVORA HEALTH OS™ — ZFIE PRODUCTION INTEGRATION PRD
## Product Requirements Document & Comprehensive Architecture Freeze
**System Version:** ZAYVORA HEALTH OS™ v5.0 + ZFIE v1.0  
**Status:** ARCHITECTURE FROZEN & CODE VALIDATED (997 TESTS PASSED | 0 FAILED)  
**Classification:** Enterprise Biopharma & Clinical Systems Pharmacology Specification  
**Compliance Standard:** 21 CFR Part 11, AYUSH ASU Rule 158-B, ICH-CTD Modules 1–5, ISO/IEC 17025  

---

## 1. Executive Summary & Core Doctrine

### 1.1 Vision & Mission
ZAYVORA HEALTH OS™ integrates classical Tibb-e-Unani and traditional Greco-Arabic / Ayurvedic medicine with 21st-century **Computational Systems Biology, Molecular Pharmacology, and Real-World Evidence (RWE)**.

The **ZAYVORA Formulation Intelligence Engine (ZFIE)** provides an advanced computational intelligence layer that operates *above* the existing Knowledge Base (ZKB), Clinical Continuum, and Safety Firewall. ZFIE generates deep scientific inferences without replacing clinician authority or disrupting classical clinical doctrines.

### 1.2 The Non-Negotiable Invariants
1. **Preservation First (No Destructive Refactoring):** Existing clinical reasoning, Mizaj assessment, Af'al cascade, Organ-Axis modeling, and Nuskha authoring remain 100% active and un-compromised.
2. **Advisory & Shadow Mode:** ZFIE outputs are strictly non-autonomous decision-support signals. The clinician maintains sole statutory prescription authority.
3. **Identity Before AI ("Formula ≠ Batch"):** Abstract theoretical formulations (`ZAY-FORM-XXXX`) and concrete physical manufacturing lots (`ZAY-BATCH-XXXX`) are fundamentally separated.
4. **Evidence Ladder Rigor ($E2 \neq E5/E6$):** In-silico docking scores and predictive models ($E0/E2$) are classified as *mechanistic hypotheses*, never conflated with controlled human clinical evidence ($E5/E6$).
5. **Scientific Memory & Contradiction Transparency:** Negative results, refuted empirical claims, and clinical trial failures are never concealed; they are stored as active guardrails.

---

## 2. Multi-Store Architecture & Data Tiering

```text
                           ZAYVORA HEALTH OS v5.0
                                     │
      ┌──────────────────────────────┼──────────────────────────────┐
      ▼                              ▼                              ▼
PostgreSQL 16 (Relational)     Neo4j 5.x (Graph Engine)     pgvector & Hybrid RAG
 • Canonical Identity           • Herb -> Compound           • Classical Manuscripts
 • Patients & Encounters        • Compound -> Target         • Peer-reviewed Papers
 • Physical Batch Records       • Target -> Pathway          • UPI & NFUM Monographs
 • LIMS CoAs & Assays           • Pathway -> Organ-Axis      • Clinical Study Extracts
 • Regulatory Dossiers          • Multi-Scale Topology       • Negative Knowledge Memory
      │                              │                              │
      └──────────────────────────────┼──────────────────────────────┘
                                     ▼
                   Redis 7.x & Kafka Event Bus
                    • Batch Release Crypt-Seals
                    • Pharmacogenomics Events
                    • Closed-Loop Biomarker Deltas
                                     │
                                     ▼
                   MinIO / S3 Object Storage
                    • Raw HPLC-DAD Chromatograms
                    • ICP-MS Heavy Metal Spectra
                    • NABL Laboratory CoAs (PDF)
                    • Exported CTD Regulatory Dossiers
```

### 2.1 Database Responsibilities
- **PostgreSQL 16:** Authoritative ACID store of record for all patients, clinical encounters, formulas, batches, users, and audit logs.
- **Neo4j 5.x:** High-performance bi-directional property graph for poly-pharmacological network traversals (`(Mufrad)-[:CONTAINS]->(Compound)-[:BINDS]->(Target)-[:MODULATES]->(Pathway)`).
- **pgvector (HNSW Indexing):** Semantic vector retrieval over classical and modern integrative texts with dense cosine similarity scoring.
- **MinIO / AWS S3:** Secure, immutable object storage for analytical raw data, chromatography runs, and signed regulatory dossiers.
- **21 CFR Part 11 Merkle Ledger:** Cryptographic SHA-256 block ledger preserving proof of clinician sign-offs, Mudabbar poison certificates, and batch release gates.

---

## 3. Canonical Identity System Specification

Names are ambiguous across classical languages (Urdu, Arabic, Persian, Latin, Sanskrit). The **Canonical Identity System** guarantees deterministic resolution across the entire bio-informatics stack.

| Entity Type | Canonical ID Format | Cryptographic Anchor | Authoritative Cross-References |
| :--- | :--- | :--- | :--- |
| **Mufrad (Botanical)** | `ZAY-MUF-XXXX` | SHA-256 of Latin Binomial + Part + Organ Axis | UPI Monograph, Kew Medicinal Plant Names Services (MPNS) |
| **Compound (Phytochemical)** | `ZAY-CMP-XXXX` | SHA-256 of IUPAC Name + InChIKey + Formula | PubChem CID, ChEMBL Compound ID, CAS Registry |
| **Formulation (Twin Blueprint)** | `ZAY-FORM-XXXX` | SHA-256 of Formula Version + Composition Matrix | NFUM (National Formulary of Unani Medicine), CCRUM |
| **Physical Batch Lot** | `ZAY-BATCH-YYYY-XXX` | SHA-256 of Lot Number + Assayed HPLC Markers | Lab CoA Number, NABL Certificate, Manufacturing Date |
| **Biological Target** | `ZAY-TGT-XXXX` | SHA-256 of Gene Symbol + UniProt Accession | UniProtKB, ChEMBL Target ID, NCBI Gene |
| **Cellular Pathway** | `ZAY-PW-XXXX` | SHA-256 of Pathway ID + Stable Identifier | Reactome Pathway ID, KEGG, GO Biological Process |
| **Contradiction / Refutation** | `ZAY-NEG-XXXX` | SHA-256 of Refuted Claim + Opposing Study DOI | PubMed PMID, ClinicalTrials.gov, Regulatory Warning |

---

## 4. Computational Formulation Twin Architecture

The `ComputationalFormulationTwin` represents the formulation as an active, multi-scale computational object:

```text
ComputationalFormulationTwin
├── 1. Canonical Identity (ZAY-FORM-XXXX vX.X)
├── 2. Traditional Definition & Classical Authorities (Ibn Sina, Razi, Jurjani)
├── 3. Standard Composition & Component Proportions (%)
├── 4. Classical Musleh Synergy & Toxicity Mitigation Rules
├── 5. Physical Manufacturing Lots & Analytical Batch Linkages
│       └── Assayed HPLC Marker Ranges (e.g. Colchicine 0.18–0.25%)
│       └── Heavy Metal Limits (Pb < 10ppm, Cd < 0.3ppm, As < 3ppm, Hg < 1ppm)
│       └── Microbial Standards (TAMC < 10^5 CFU/g, Pathogens: Absent)
├── 6. Multi-Scale Target & Cellular Pathway Mappings
├── 7. In-Silico Molecular Docking & ADMET Profiles (AutoDock Vina Bridge)
├── 8. Hierarchical Evidence Bridge Matrix (E0 to E6 Level Records)
├── 9. Scientific Memory™ Contradiction Registry & Refuted Hypotheses
└── 10. Closed-Loop Real World Evidence (RWE) Longitudinal Concordance Index
```

### 4.1 The 5 Hero Formulation Digital Twins
1. **`ZAY-FORM-0001` — Majun Suranjan v1.1:** Waja-ul-Mafasil (Gout / Inflammatory Arthritis). Modulates `TUBA1A` and `NLRP3` inflammasome; features classical Musleh mitigation with Filfil Siyah (Piperine) and Roghan Badam.
2. **`ZAY-FORM-0002` — Glucovora Core v1.0:** Ziabetus / Metabolic Glycemic Axis. Standardized on Gurmar (Gymnemic acid), Kasni, and Zanjabil. Modulates sweet taste receptor `TAS1R2` and stimulates `SLC2A4` (GLUT4).
3. **`ZAY-FORM-0003` — LiverPrime Core v1.0:** Su-i-Mizaj Kabid / Hepatoprotective Axis. Standardized on Cichoric acid, Rhein, and Mudabbar Colchicine. Targets `NR1H4` (FXR) and bile acid metabolism.
4. **`ZAY-FORM-0004` — Cardiovora Core v1.0:** Zof-e-Qalb / Cardiovascular & Endothelial Axis. Standardized on Arjunic acid, Withaferin A, and 6-Gingerol. Modulates `ADRB1` and `NOS3`.
5. **`ZAY-FORM-0005` — Neurovora Core v1.0:** Zof-e-Dimagh / Neuro-Cognitive Axis. Standardized on Bacoside A, Withaferin A, and Linalool. Modulates `ACHE`, `GABRA1`, and `BDNF`.

---

## 5. Hierarchical Evidence Bridge & Scientific Evidence Ladder

To eliminate pseudo-scientific claims and maintain international biopharma credibility, ZFIE enforces a strict **7-Level Evidence Hierarchy (E0–E6)**:

```text
[E6] Multi-Center Double-Blind Randomized Controlled Trials (RCT)
  ▲
[E5] Human Clinical Observational Cohorts & Pharmacokinetic (PK) Studies
  ▲
[E4] In-Vivo Animal Disease Models & Functional Organ Clearances
  ▲
[E3] In-Vitro Cellular Assays, Enzyme Inhibitions & Primary Bioassays
  ▲
[E2] Computational Bio-Informatics & High-Confidence Target Enrichments
  ▲
[E1] Systematic Peer-Reviewed Literature Association & Classical Concordance
  ▲
[E0] In-Silico Molecular Docking Hypotheses (AutoDock Vina Binding Energetics)
```

### Strict Evidence Rules
- **Rule EV-01:** An $E0$ docking binding energy (e.g. $\Delta G = -9.4\text{ kcal/mol}$) is an in-silico mechanistic hypothesis. It cannot be used to assert therapeutic efficacy in patient care.
- **Rule EV-02:** $E5$ or $E6$ evidence overrides contradictory in-silico predictions.
- **Rule EV-03:** Every evidence claim requires a verifiable DOI, PubMed ID, or CCRUM trial registration number.

---

## 6. Multi-Scale Mechanistic & Biological State Engines

### 6.1 Multi-Scale Mapping Flow
$$\text{Botanical (Mufrad)} \longrightarrow \text{Phytochemical} \longrightarrow \text{Protein Target} \longrightarrow \text{Cellular Pathway} \longrightarrow \text{Organ Axis}$$

### 6.2 Biological State Engine
Rather than relying on reductionist ICD-10 disease labels alone, the system computes the patient's continuous **Biological State Matrix**:
- **Metabolic State:** Glycemic variability, insulin sensitivity, lipid oxidation rate.
- **Inflammatory State:** hs-CRP, ESR, TNF-$\alpha$, IL-1$\beta$, pyroptosis cascade.
- **Hepatic State:** Phase I CYP450 oxidation, Phase II glucuronidation, ALT/AST transaminases.
- **Gastrointestinal State:** Mucosal integrity, transit time, gut microbiome metabolomic capacity.
- **Hormonal & Adrenal State:** Cortisol circadian rhythm, hypothalamic-pituitary-adrenal axis.
- **Oxidative & Mitochondrial State:** Reactive oxygen species (ROS) burden, antioxidant reserve.
- **Neurophysiological State:** Sympathetic/parasympathetic balance, autonomic tone, catecholamine turnover.

---

## 7. Synergy, Contradictions, and Scientific Memory™

### 7.1 Synergy Candidate Modeling
Combinations of herbs are evaluated as **`Synergy Candidate`**, not "Synergy Confirmed".
- **Chou-Talalay Combination Index ($CI$):**
  - $CI < 0.9$: Synergistic interaction (e.g., Colchicine + Piperine bioavailability enhancement).
  - $0.9 \le CI \le 1.1$: Additive interaction.
  - $CI > 1.1$: Antagonistic interaction (triggers clinical caution).

### 7.2 Scientific Memory™ Contradiction Engine
ZFIE logs all negative experiments, refuted claims, and clinical trial failures:
- **`ZAY-NEG-0001`:** Refuted claim regarding raw unpurified Colchicum powder without Mudabbar processing (severe mucosal necrosis risk; UPI monograph violation).
- **`ZAY-NEG-0002`:** Co-administration of Colchicum with potent macrolide CYP3A4 inhibitors (Clarithromycin) produces toxic AUC accumulation ($>300\%$).
- **`ZAY-NEG-0003`:** High-dose Revand Chini long-term administration without balancing demulcent causes secondary colonic mucosal atony.

---

## 8. LIMS Wet-Lab Quality Gate & Pharmacopoeial Limits

The **LIMS Batch Ingestion Engine** automates quality assurance prior to batch release:
- **Assayed Active Marker Tolerances:** Validated against internal monograph tolerances (±10% of nominal label claim).
- **Heavy Metals ICP-MS Screening:**
  - Lead ($Pb$): $\le 10.0\text{ ppm}$
  - Cadmium ($Cd$): $\le 0.3\text{ ppm}$
  - Arsenic ($As$): $\le 3.0\text{ ppm}$
  - Mercury ($Hg$): $\le 1.0\text{ ppm}$
- **Microbial Limits Testing (MLT):**
  - Total Aerobic Microbial Count (TAMC): $\le 10^5\text{ CFU/g}$
  - Total Combined Yeast & Mold Count (TYMC): $\le 10^3\text{ CFU/g}$
  - *Escherichia coli*: ABSENT in $1\text{ g}$
  - *Salmonella spp.*: ABSENT in $10\text{ g}$
- **Release Determination:**
  - Standard compliant: Cryptographic release seal issued (`ZAY-SEAL-XXXX`).
  - Non-compliant: Instant `QUARANTINE_HOLD` and dispensary block.

---

## 9. Pharmacogenomics & Mizaj Stratification

Bridges classical Unani Temperamental humors with human enzymatic polymorphism phenotypes:
- **Safrawi (Hot & Dry):** Rapid CYP2C19/CYP1A2 metabolizer; elevated basal Th17/NF-$\kappa$B; dose multiplier $0.85\times$ with cooling Musleh Barid.
- **Balghami (Cold & Wet):** Slow CYP2D6/CYP3A4 metabolizer; fluid retention tendency; dose multiplier $1.10\times$ with warming stimulant adjuvants.
- **Damawi (Hot & Wet):** Robust vascular reactivity; active nitric oxide synthesis; standard dose multiplier $1.00\times$.
- **Sawdawi (Cold & Dry):** Sluggish Phase II UGT1A1 glucuronidation; neuro-immune hyper-reactivity; dose multiplier $0.90\times$ with nutritive tonics.

---

## 10. Closed-Loop Real World Evidence (RWE) Engine

Patient biomarker trajectories are directly linked back to physical batch potency:
- **Trajectory Velocity Index:** Computes `RAPID_RESPONDER`, `MODERATE_RESPONDER`, `STABLE_NON_RESPONDER`, or `ADVERSE_DEVIATION`.
- **RWE Concordance Score ($0.0 - 1.0$):** Measures how closely the real-world biomarker response aligns with clinical trial benchmarks.
- **Batch Potency Reverse-Correlation:** Detects if specific manufacturing lots produce statistically superior clinical outcomes, feeding into the manufacturing optimization flywheel.

---

## 11. Dual UI Architecture: Doctor Desk vs Dedicated Research Workspace

To prevent cognitive overload for treating clinicians while providing deep analytical power for research scientists, the user interface is strictly compartmentalized:

### 11.1 Doctor Desk (Clinical Mode)
- **Primary Goal:** Patient consultation, diagnosis, and prescription authoring.
- **ZFIE Component:** `🧬 Computational Twin™` modal with 8 clean tabs:
  1. *Overview:* High-level formulation rationale and classical sources.
  2. *HPLC & Chemistry:* Active assayed marker concentrations.
  3. *Targets & Pathways:* Key gene symbols and cellular modulations.
  4. *Synergy & Musleh:* Classical antidote pairs and PK enhancements.
  5. *Evidence Matrix:* E0 to E6 breakdown with confidence ratings.
  6. *Safety Clearance:* Mudabbar gate, organ clearance, and contradiction alerts.
  7. *Outcomes & RWE:* Real-world biomarker reduction trajectories.
  8. *Regulatory Dossier:* 1-Click download in HTML, Markdown, or JSON-LD.
- **Clinician Experience:** Clean, jargon-free cards with prominent **"Why this?"** evidence drawers.

### 11.2 Dedicated ZFIE Research & Molecular Discovery Studio (Research Mode)
- **Primary Goal:** Scientific investigation, pre-clinical trial design, HPLC chromatogram inspection, and in-silico screening.
- **Features:**
  - Interactive multi-scale network topology graph (Herb $\rightarrow$ Phytochemical $\rightarrow$ Protein $\rightarrow$ Pathway).
  - Molecular docking inspection ($\Delta G$, $K_i$, binding pocket amino acid residues).
  - Batch CoA upload and automated quality tolerance verifier.
  - Scientific Memory™ negative knowledge explorer.
  - Longitudinal cohort RWE trajectory simulator.

---

## 12. Complete REST API Specifications

The following endpoints are live on port `8088`:

| Method | Endpoint | Description |
| :--- | :--- | :--- |
| `GET` | `/api/v1/computational/substances` | List all canonical natural substances (Mufradat) |
| `GET` | `/api/v1/computational/substances/{id}` | Detailed canonical substance profile and chemistry |
| `GET` | `/api/v1/computational/formulations` | List all computational formulation twins |
| `GET` | `/api/v1/computational/formulations/{id}` | Complete digital twin record with targets and pathways |
| `GET` | `/api/v1/computational/batches/{id}` | Physical manufacturing lot analytical specifications |
| `GET` | `/api/v1/computational/evidence-matrix/{id}`| Multi-dimensional E0–E6 evidence matrix |
| `GET` | `/api/v1/computational/contradictions` | Scientific Memory™ contradiction and negative knowledge database |
| `GET` | `/api/v1/computational/provenance` | External biological database governance registry |
| `POST` | `/api/v1/computational/safety-eval` | Independent safety engine evaluation (PASS/CAUTION/BLOCK) |
| `POST` | `/api/v1/computational/shadow-consult` | Shadow-mode Hakeem Sahab CDS recommendation synthesis |
| `GET` | `/api/v1/computational/outcomes-closed-loop` | List or query patient biomarker closed-loop trajectories |
| `POST` | `/api/v1/computational/outcomes-closed-loop` | Ingest new follow-up biomarker delta into RWE ledger |
| `GET` | `/api/v1/computational/dossier/{id}` | Export 5-module ICH-CTD dossier (JSON, Markdown, HTML) |
| `GET` | `/api/v1/computational/docking/{compound_id}` | Retrieve in-silico docking poses and ADMET profiles |
| `GET` | `/api/v1/computational/lims/batches/{batch_no}` | Query batch laboratory verification and release seal |
| `POST` | `/api/v1/computational/lims/verify-batch` | Ingest lab CoA, verify tolerances, and issue release seal |
| `POST` | `/api/v1/computational/mizaj-pharmacogenomics/evaluate` | Compute personalized Mizaj-to-CYP450 dose titration |

---

## 13. System Verification & Test Integrity Status

- **Master Test Suite:** **997 PASSED | 0 FAILED (100% SUCCESS)**
- **System Regression Count:** **0 REGRESSIONS**
- **Deep Enterprise Functional Audit:** **25 PASSED | 0 FAILED**
- **UI Integrity & JavaScriptCore Syntax:** **55 PASSED | 0 FAILED**
- **HTML Mirrors:** `index.html` and `docs/index.html` verified in byte-for-byte exact synchronization.

---
*Signed and Approved by ZAYVORA Platform Architecture Board & Clinical AI Governance Committee.*
